![]() |
|
|
Vol. 282, Issue 3, 1337-1344, 1997
Department of Pharmacology, James H. Quillen College of Medicine,
East Tennessee State University, Johnson City, Tennessee
The primary goal of this study was to determine the extent that
selective muscarinic receptor antagonists could discriminate between
the chronotropic and coronary vasoconstrictor responses to
acetylcholine in isolated rat hearts perfused at constant flow rate.
Bolus injections of acetylcholine caused dose-dependent decreases in
heart rate and increases in perfusion pressure. The ED50
(95% confidence) of acetylcholine for decreasing rate was 0.463 (0.336-0.640) nmol and the dose that increased perfusion pressure by
30 mm Hg (ED30 mmHg
) was 3.19 (2.00-5.08)
nmol. The M2 selective antagonist methoctramine (3.16 µM)
produced a 307-fold increase in the ED50 for bradycardia
but had no significant effect on the pressor response to acetylcholine.
In marked contrast, the M3 antagonist
hexahydrosiladifenidol displayed a distinct preference for inhibiting
coronary vasoconstrictor responses to acetylcholine. When present at
316 nM, this drug produced a 66-fold increase in the ED30
mmHg
but only a 6-fold increase in the ED50
for bradycardia. The M1 selective antagonist pirenzepine (316 nM) produced a 5- to 7-fold increase in both parameters. Pretreatment with pertussis toxin (25 µg/kg, i.p.) essentially eliminated acetylcholine-evoked bradycardia although pressor responses persisted with some reduction. These observations demonstrate that
cardiac and coronary vascular effects of acetylcholine can be clearly
discriminated with specific muscarinic antagonists. Furthermore, they
provide evidence that the M3 receptor subtype mediates the
vasoconstrictor effect of acetylcholine on resistance vessels in rat
heart.
This article has been cited by other articles:
![]() |
S. Ji, T. Tosaka, B. H. Whitfield, A. N. Katchman, A. Kandil, B. C. Knollmann, and S. N. Ebert Differential Rate Responses to Nicotine in Rat Heart: Evidence for Two Classes of Nicotinic Receptors J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 893 - 899. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. N. Hardouin, K. N. Richmond, A. Zimmerman, S. E. Hamilton, E. O. Feigl, and N. M. Nathanson Altered Cardiovascular Responses in Mice Lacking the M1 Muscarinic Acetylcholine Receptor J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 129 - 137. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhang and D. B. Hoover Signaling Mechanisms for Muscarinic Receptor-Mediated Coronary Vasoconstriction in Isolated Rat Hearts J. Pharmacol. Exp. Ther., April 1, 2000; 293(1): 96 - 106. [Abstract] [Full Text] |
||||